<DOC>
	<DOCNO>NCT01401023</DOCNO>
	<brief_summary>This prospective , non-comparative , interventional , observational pilot study safety pharmacokinetics intravenous ( IV ) tigecycline conjunction standard oral therapy patient know mild severe confirm Clostridium difficile associate diarrhea ( CDAD ) .</brief_summary>
	<brief_title>Pharmacokinetics Safety Tigecycline Treatment Clostridium Difficile Associated Diarrhea ( CDAD )</brief_title>
	<detailed_description>The intervention add Tigecycline ( standard dos ) standard oral therapy CDAD . Patients observe clinical outcome relapse CDAD .</detailed_description>
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Tigecycline</mesh_term>
	<mesh_term>Minocycline</mesh_term>
	<criteria>non pregnant adult ( â‰¥18 year old ) diagnosis mild severe CDAD ( initial recurrent ) positive C. difficile toxin assay along clinical symptom ( watery stools , fever , abdominal pain ) . Patients receive minimum 3 day tigecycline . pregnant patient allergy tetracycline ( tigecycline ) antibiotic patient lifethreatening illness .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>